Alphyn is developing first-in-class Multi-Target Therapeutics® for severe and prevalent skin diseases based on its AB-101 platform, which has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety, efficacy, and regulatory marketing authorization advantages. We are initially targeting the $118 Billion atopic dermatitis (AD) market. After only 3½ years, Alphyn’s first drug candidate, topical zabalafin (formerly AB-101a) completed two Phase 2a clinical trials in AD with market-leading results, providing a faster path to regulatory approval and huge commercial opportunity, with clinical results pointing to a potential “drug of choice” for this vast 800 million patient population. Our second candidate is for epidermolysis bullosa (EB), a collection of rare and life-threatening skin diseases.